Elixinol Wellness Limited
ELLXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | 0.15 | 0.15 |
| FCF Yield | -75.39% | -36.22% | -13.48% | -6.05% |
| EV / EBITDA | -1.35 | -1.21 | -6.41 | -15.04 |
| Quality | ||||
| ROIC | -11.21% | -82.95% | -90.43% | -71.35% |
| Gross Margin | 37.72% | 41.36% | -46.29% | -66.98% |
| Cash Conversion Ratio | – | 0.37 | 0.77 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.46% | -3.97% | -22.25% | -32.76% |
| Free Cash Flow Growth | -27.17% | 66.01% | 43.16% | 37.41% |
| Safety | ||||
| Net Debt / EBITDA | -0.21 | -0.08 | 0.11 | 0.66 |
| Interest Coverage | -28.85 | -63.98 | -140.87 | -169.66 |
| Efficiency | ||||
| Inventory Turnover | 2.39 | 1.32 | 5.93 | 7.08 |
| Cash Conversion Cycle | 120.48 | 218.62 | 60.63 | 44.19 |